Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger, Inc. (Nasdaq: SDGR) is hosting its second annual Educator's Day to discuss the integration of computational tools in education. The event, featuring live webinars from esteemed educators, aims to equip K-12 and university students with modern scientific skills. Keynote speaker Maria Gallardo-Williams highlighted the effectiveness of virtual reality labs developed during the COVID-19 pandemic, which assisted over 50 universities. Schrödinger's software platform accelerates drug and materials discovery, emphasizing hands-on learning and bridging technology gaps in education.

Schrödinger (Nasdaq: SDGR) announced its participation in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 3:30 p.m. ET. The live presentation will be accessible in the investors section of Schrödinger's website and archived for seven days. Schrödinger is renowned for its innovative physics-based software platform that accelerates the discovery of therapeutics and materials, engaging biopharmaceutical and industrial sectors worldwide.

Schrödinger, Inc. (Nasdaq: SDGR) has appointed Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi, a former executive vice president at Red Hat, will also serve on the Audit Committee. His extensive experience in enterprise software is expected to support Schrödinger's growth and mission to enhance human health. Schrödinger specializes in a physics-based software platform that accelerates the discovery of therapeutics and materials, aiming to improve efficiency and reduce costs significantly compared to traditional methods.

Schrödinger (Nasdaq: SDGR) announced its participation in the Citi Biotech Virtual Co-Panel Day on May 18, 2022, at 10:00 a.m. ET. Karen Akinsanya, president of R&D, Therapeutics, will discuss Software, AI, and Bioinformatics in Drug Development. The panel will be accessible live via the investors section of Schrödinger’s website and will be archived for a week afterward. Schrödinger's innovative software platform significantly enhances the discovery of therapeutics and materials, supporting clients globally since its inception in 1990.

Schrödinger, Inc. (SDGR) reported a strong first quarter of 2022 with total revenue of $48.7 million, representing a 51% increase year-over-year. Software revenue reached $33.1 million, a 26% rise, driven by customer adoption. Gross profit was $28 million, a 73% increase, while the company recorded a net loss of $34.5 million. Schrödinger is on track with its pipeline, notably planning an IND submission for its MALT1 inhibitor, SGR-1505, in the first half of 2022. The company maintains its 2022 financial outlook, predicting total revenue of $161 million to $181 million.

Schrödinger (Nasdaq: SDGR) will report its Q1 2022 financial results on May 4, 2022, after market close. The company will host a conference call at 4:30 p.m. ET to discuss the results. Schrödinger uses a physics-based software platform for drug and materials discovery, leading to rapid and cost-effective development. Founded in 1990, it collaborates with global biopharmaceutical and industrial firms, academic institutions, and government labs, employing over 650 staff across 70 countries.

Schrödinger, Inc. (Nasdaq: SDGR) has granted stock options for 101,715 shares to 30 newly hired employees as an incentive for their employment acceptance. The options were issued under the company’s 2021 Inducement Equity Incentive Plan with an exercise price of $29.82, equal to the closing stock price on April 15, 2022. The vesting period is structured, with U.S. employees vesting monthly over four years, while employees in India and Japan will vest annually over three years. This move aims to enhance talent acquisition and retention as Schrödinger continues to innovate in drug discovery.

Schrödinger, Inc. (Nasdaq: SDGR) presented promising preclinical data on its Wee1 inhibitors at the AACR Annual Meeting. These inhibitors demonstrate strong anti-tumor activity and potential for monotherapy and combination therapy. The company plans to identify a Wee1 development candidate by 2022 and submit an IND application to the FDA in 2023. The study highlighted a compound, STC-8123, showing high selectivity and sustained anti-tumor effects without significant side effects, indicating a favorable dosing regimen.

Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of non-statutory stock options for 42,425 shares to 17 new employees on March 15, 2022. This grant, part of the 2021 Inducement Equity Incentive Plan, serves as an inducement for employment acceptance, compliant with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $28.81 per share, equal to the closing price on the grant date. Options vest over four years, with different vesting schedules for U.S. and India-based hires.

Schrödinger is focused on enhancing drug discovery through its physics-based software platform.